Status:
WITHDRAWN
Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes
Lead Sponsor:
Institut de Recherches Cliniques de Montreal
Collaborating Sponsors:
Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In the unfortunate case of severe hypoglycaemia, glucagon is the first-line treatment because of its potent and rapid action starting as fast as 5 minutes after subcutaneous or intramuscular injection...
Detailed Description
In the unfortunate case of severe hypoglycaemia, glucagon is the first-line treatment because of its potent and rapid action starting as fast as 5 minutes after subcutaneous or intramuscular injection...
Eligibility Criteria
Inclusion
- Males and females ≥ 18 years of old
- Clinical diagnosis of type 1 diabetes for at least two years.
Exclusion
- Clinically significant nephropathy (MDRD \< 60 mL/min/1.73 m2).
- Pregnancy
- Severe hypoglycemic episode within two weeks of screening
- Current use of glucocorticoid medication (except low stable dose)
- Pheochromocytoma or primary adrenal insufficiency (e.g. Addison's disease)
- Medical condition likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01828125
Start Date
April 1 2013
End Date
December 1 2013
Last Update
December 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada, H2W 1R7